Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era
Key Points. Twenty-eight percent of patients treated with caplacizumab had persistent ADAMTS13 activity <30% within 30 + 28 days after PEX.In patients with A